The outlook for precision medicine for the treatment of chronic hepatitis C infection: challenges and opportunities

IF 1 Q4 PHARMACOLOGY & PHARMACY

Expert Review of Precision Medicine and Drug Development Pub Date : 2020-06-09 DOI:10.1080/23808993.2020.1764346

M. Frías, A. Rivero-Juarez, I. Machuca, Á. Camacho, A. Rivero

引用次数: 0

Abstract

ABSTRACT Introduction This review focuses on the milestones and challenges of precision medicine in the natural history of HCV infection. Areas covered The manuscript summarizes the genetic and viral factors identified as predictive of outcome in HCV patients and discusses opportunities for a precision medicine approach to the management of patients with HCV infection. Special emphasis will be placed on the factors associated with response to treatment as well as other factors that can help the clinician in the management of patients after sustained virological response. Expert opinion The establishment of DAAs in recent years has led to a paradigmatic change in the natural history of hepatitis C virus infection. However, there are still challenges that precision medicine must solve, especially in the management of patients at high risk of liver complications after sustained virological response.

查看原文本刊更多论文

精准医学治疗慢性丙型肝炎感染的前景:挑战与机遇

本文综述了HCV感染自然史中精准医学的里程碑和挑战。该手稿总结了被确定为HCV患者预后预测的遗传和病毒因素，并讨论了采用精准医学方法管理HCV感染患者的机会。将特别强调与治疗反应相关的因素，以及可以帮助临床医生在持续病毒学反应后管理患者的其他因素。专家意见近年来DAAs的建立导致了丙型肝炎病毒感染自然史的典型变化。然而，精准医学仍然面临着必须解决的挑战，特别是在持续病毒学反应后肝脏并发症高风险患者的管理方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Precision Medicine and Drug Development PHARMACOLOGY & PHARMACY-

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Expert Review of Precision Medicine and Drug Development publishes primarily review articles covering the development and clinical application of medicine to be used in a personalized therapy setting; in addition, the journal also publishes original research and commentary-style articles. In an era where medicine is recognizing that a one-size-fits-all approach is not always appropriate, it has become necessary to identify patients responsive to treatments and treat patient populations using a tailored approach. Areas covered include: Development and application of drugs targeted to specific genotypes and populations, as well as advanced diagnostic technologies and significant biomarkers that aid in this. Clinical trials and case studies within personalized therapy and drug development. Screening, prediction and prevention of disease, prediction of adverse events, treatment monitoring, effects of metabolomics and microbiomics on treatment. Secondary population research, genome-wide association studies, disease–gene association studies, personal genome technologies. Ethical and cost–benefit issues, the impact to healthcare and business infrastructure, and regulatory issues.